# The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

> **NCT04644185** · PHASE2,PHASE3 · TERMINATED · sponsor: **Sinocelltech Ltd.** · enrollment: 102 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** SCTA01
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04644185
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-27
- **Primary completion:** 2021-12-29
- **Final completion:** 2022-02-11
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** Preclinical test showed reduced efficacy
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04644185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04644185, "The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04644185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*